PROMO!
First order? Get 10% OFF with this code: 1storder
PROMO!
First order? Get 10% OFF with this code: 1storder
Our Product Categories
Human Menopausal Gonadotropin (HMG) peptide is a synthetic compound derived from gonadotropins, which are natural hormones important for reproduction. It contains two main hormones: follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Both of these are vital for how the reproductive system develops and works. HMG peptide is typically taken from the urine of women after menopause, because their bodies naturally produce high levels of these hormones.
In research and clinical settings, HMG peptide is crucial for studying hormonal interactions, particularly fertility, ovarian function, and spermatogenesis. Because it mimics the body’s natural gonadotropins, it’s a valuable tool for reproductive biology and developing new infertility treatments. Potential study fields include its impact on cellular processes, hormone signaling, and its potential for treating reproductive health issues.
Molecular Formula: C9H180
Molecular Weight: 142.24 g/mol
Synonyms: human Menopausal Gonadotropin
Human Menopausal Gonadotropin peptide works by mimicking two natural hormones: follicle-stimulating hormone (FSH) and luteinizing hormone (LH).
These hormones are produced by the pituitary gland and play a key role in reproduction. hMG peptide binds to FSH receptors (FSHR) and LH/hCG receptors (LHCGR) found on ovarian cells in females and testicular cells in males.
In women, it helps ovarian follicles grow and mature, preparing them for ovulation.
In men, it increases testosterone production and supports sperm development.
Researchers study hMG peptide to better understand its role in hormone signaling, reproductive health, and its potential use in infertility treatments.
Ovulation induction in anovulatory women: Research has shown that the HMG peptide is effective for ovulation induction in anovulatory women, including those with PCOS. A study found that pulsatile HMG administration led to ovulation in 86% of cycles for women with prolonged anovulatory infertility, with a 40% pregnancy rate.
In women with PCOS, combining letrozole (2.5 mg) with HMG achieved an 85% ovulation rate, better endometrial receptivity, and increased mono-follicle development [3]. The peptide has been approved for single follicle development in anovulation and multifollicular stimulation in ART protocols.
Controlled ovarian stimulation (COS) for IVF / ART: HMG peptide is widely used in controlled ovarian stimulation (COS) for IVF/ART to stimulate multiple follicles for higher oocyte retrieval. A meta-analysis found HMG achieved higher clinical pregnancy rates (RR ~1.22) compared to recombinant FSH in down-regulated IVF cycles [4].
Highly purified HMG (HP-hMG) further improved outcomes, showing significantly higher implantation (20% vs. 8.1%) and pregnancy rates (47.2% vs. 19.4%) compared to traditional HMG [5]. Research has demonstrated that modern HMG formulations are effective, safe, and support successful ART outcomes [6].
Endometrial receptivity and follicle development: Research has shown that HMG peptide enhances endometrial receptivity and controlled follicle development. In a PCOS RCT, letrozole (2.5 mg) + HMG resulted in higher “type B” endometrial tissue (88.5% vs 69.0%) and monofollicular development (67.8% vs 46.0%) compared to a higher letrozole dose [3]. Monitoring HMG cycles with serum estradiol (E2) and ultrasound is crucial, aiming for an E2 window of ≥1000 pg/mL over 9-12 days, optimizing follicular growth and endometrial preparation for implantation [1].
Induction of spermatogenesis in men with hypogonadotropic hypogonadism: Studies show that combining HMG peptide and hCG successfully helps men with hypogonadotropic hypogonadism produce sperm. This regimen increases testicular volume (from ~3.08 mL to ~8.92 mL), testosterone production, and secondary sexual characteristics [7].
In a study, 81.2% of patients showed testicular growth, and 2 achieved spermatogenesis [8]. Compared to FSH + testosterone, hCG + HMG was superior in inducing and maintaining spermatogenesis, highlighting its role in restoring fertility while avoiding the suppressive effects of exogenous testosterone [9].
Benefit in idiopathic oligozoospermia: Research suggests that HMG peptide, combined with hCG, benefits men with idiopathic oligozoospermia, particularly those with medium-to-high inhibin B levels. A 2019 trial showed significant improvements in sperm concentration, motility, morphology, and total motile sperm count after three months of therapy, alongside reduced DNA fragmentation [10].
Earlier studies reported pregnancies in the treated group, despite no statistical differences in sperm parameters. These findings highlight hCG/HMG therapy’s potential in enhancing fertility in select oligozoospermic men.
Testicular development and testosterone production: Research has demonstrated that HMG peptide, often combined with hCG, effectively stimulates testicular growth and testosterone production in men with hypogonadotropic hypogonadism. Studies show significant increases in testicular volume, penile size, and intratesticular testosterone, promoting spermatogenic cell maturation [11].
Unlike traditional testosterone therapy, HMG avoids suppressing the hypothalamic-pituitary-gonadal axis, supporting fertility while normalizing androgen levels. This treatment is highly effective in inducing pubertal development and restoring reproductive function in affected individuals [9].
Buy hMG Pre-Mixed Peptide Pen from Peptide Works. Each 75 IU cartridge can be purchased individually or as part of a complete kit that includes a reusable pen, needle tips, and a carry case for convenient and precise preparation.
[1] Friedler, S., & Diamant, Y. Z. (1987). Ovulation induction with pulsatile human menopausal gonadotropin (HMG) administration. European Journal of Obstetrics and Gynecology and Reproductive Biology, 25(4), 303-313.
[2] B Lunenfeld, W Bilger, S Longobardi, V Alam, et al (2019) The Development of Gonadotropins for Clinical Use in the Treatment of Infertility – Frontiers in Endocrinology (Lausanne), 2019 Jul 3, Volume 10, Page 429.
[3] J Li, Y Peng, X Dai, L Zhang, et al (2025) Human menopausal gonadotropin (HMG) combined different doses of letrozole for treating anovulatory infertility in patients with polycystic ovary syndrome: a randomized controlled trial – Journal of Assisted Reproduction & Genetics, 2025 Apr 7, Volume 42 (Issue 6), Pages 1895–1906.
[4] M van Wely, L G Westergaard, P M M Bossuyt, and F van der Veen (2003) Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis – Fertility & Sterility, 2003 Nov, Volume 80 (Issue 5), Pages 1086-93.
[5] K A Rao, G Khanna, H Bavishi, N S Reddy, et al (2025) Clinical efficacy and safety of two highly purified human menopausal gonadotropins in women undergoing in vitro fertilization – Reproduction & Fertility, 2025 Jun 10, Volume 6 (Issue 2), Page e240132.
[6] R Orvieto, S Meltcer, G Liberty, J Rabinson, et al (2010) Human menopausal gonadotropin versus highly purified-hMG in controlled ovarian hyperstimulation for in-vitro fertilisation: does purity improve outcome? – Gynecological Endocrinology, 2010 Oct, Volume 26 (Issue 10), Pages 733-5.
[7] Fu-song Di, Yu-gui Cui, and Yue Jia (2005) [The application of gonadotropin in treatment of male central hypogonadism] – Zhonghua Nei Ke Za Zhi, 2005 Nov, Volume 44 (Issue 11), Pages 836-9.
[8] G Schaison, J Young, M Pholsena, et al (1993) Failure of combined follicle-stimulating hormone-testosterone administration to initiate and/or maintain spermatogenesis in men with hypogonadotropic hypogonadism – The Journal of Clinical Endocrinology & Metabolism, Volume 77, Issue 6, 1 December 1993, Pages 1545–1549.
[9] Julius Fink, Hisamitsu Ide, and Shigeo Horie (2024) Management of Male Fertility in Hypogonadal Patients on Testosterone Replacement Therapy – Medicina 2024, 60(2), 275.
[10] Nan Zhao, Xi-Lan Lu, Jun-Tao Li, and Jian-Min Zhang (2019) Treatment of idiopathic oligozoospermia with combined human chorionic gonadotropin/human menopausal gonadotrophin: A randomised, double-blinded, placebo-controlled clinical study – Andrologia, 2019 Jul, Volume 51 (Issue 6), Pages e13271.
[11] E C Alexander, D Faruqi, R Farquhar, A Unadkat, et al (2024) Gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism: systematic review and meta-analysis – European Journal of Endocrinology, Volume 190, Issue 1, January 2024, Pages S1–S11.
The answers to the most frequently asked questions about hMG peptide.
Buy hMG Peptide Nasal Spray from Peptide Works. Offered in 15ml and 30ml glass spray bottles, this non-invasive administration route provides a simple and effective option for consistent application.
The hMG peptide contains hormones that mimic natural signals in the body linked to growth and reproduction. It combines FSH and LH, two key gonadotropins that work together to support hormone balance and cell activity. Researchers study hMG for its potential role in reproductive and endocrine functions.
The hMG peptide and hCG peptide are both studied for their roles in reproductive hormone activity. hMG contains FSH and LH, which support hormone signaling linked to egg and sperm cell growth. hCG mimics LH, mainly linked to triggering final stages of cell development and hormone release. Researchers often compare them to study hormonal regulation and fertility pathways.
The hMG peptide is regulated differently across countries. In the United States, the FDA classifies hMG (human menopausal gonadotropin) as a prescription-only medication when used clinically. However, research-grade hMG peptides are available for laboratory and scientific use under research-use guidelines. Other countries may have different import or labeling rules, so buyers should ensure compliance with their local regulations before ordering.
In clinical research, hMG has been associated with hormone-related responses such as mild bloating, mood changes, or localized irritation after administration. These observations come from medical studies, not from laboratory testing. Our hMG peptide is supplied for research and scientific analysis, allowing professionals to study its properties under controlled conditions.
This blog takes a look at the potential of HMG (Human Menopausal Gonadotropin) treatment in helping manage menopause symptoms. It explores the hormonal changes that occur during this stage, the role of peptides such as HMG and Sermorelin in ongoing research, and their effects on mood, energy, and overall well-being. With a focus on current scientific studies, it highlights promising developments in peptide therapy.
This blog discusses the roles of HMG and hCG hormones in fertility research, with a focus on ovarian stimulation, egg maturation, and embryo quality. It also highlights the timing for egg retrieval, factors that influence implantation, and the importance of individualized luteal support. Peptide Works offers high-quality research peptides that contribute to ongoing advancements in fertility treatment studies.
This blog explores how peptides may help address brain fog during menopause a common cognitive concern linked to hormonal shifts, stress, and aging. It also highlights research involving peptides such as Semax, Selank, Epithalon, and BPC-157, exploring their potential to enhance memory, focus, mood, and neural repair, contributing to improved cognitive clarity.
ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.
DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Peptide Works website: https://peptide-works.com/ is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.
